Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Indication: Nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS)
Study: Prospective, explorative, two-group, non-randomized, phase II trial (NITraSarc) Advanced, previously treated lipo-leiomyosarcoma (Group A: GA) (n=43) and non-L-sarcomas (Group B: GB) (n=49) Early combination cohort (ECC): Trabectedin x2 cycle
New Protocol: Nivolumab(N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)
Study: Phase III, randomized, controlled study (SWOG S1826) Previously untreated pts were ≥12 years (y) with stage 3-4 HL N-AVD (n=489) vs. BV-AVD (n=487) Efficacy: 1-year PFS: 94% vs 86%,
New Indication: Cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer (EMPOWER-Lung-3)
Study: Double-blind, placebo-controlled, phase 3 study Untreated advanced or metastatic NSCLC Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154)) Efficacy: mOS : 21.9 vs. 13.0 mos
New Protocol – A Phase 2 Study of Pemigatinib in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement 8 (FIGHT-203)
Study: Phase 2, open label, multicenter trial Myeloid/Lymphoid Neoplasms 28 patients ≥1 prior therapy Pemigatinib 13.5 mg daily (2 wks; 1 wk off) No prior therapy Pemigatinib 13.5
New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Study: Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles Efficacy:
New Indication: Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA)
Study: Open-label, multicentre, phase 3 study Untreated CLL or SLL Patients without del (17) (p13·1) zanubrutinib (group A; n=241) or bendamustine–rituximab (group B; n=238) and patients with del(17) (p13·1)
New Indication: Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312)
Study: Open-label, randomised, phase 3 trial Previously untreated advanced hepatocellular carcinoma Cabozantinib 40 mg plus atezolizumab 1200 mg IV every 3 weeks (N:432), sorafenib 400 mg twice Daily (n:217), or
New Reference: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
Study: Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 weeks) plus chemotherapy (n:566) or chemotherapy (n:281) Efficacy:
New Reference: Nivolumab plus cabozantinib in first-line treatment for advanced renal cell carcinoma
Study: Open-label, randomised, phase 3 trial (CheckMate 9ER) Previously untreated advanced or metastatic clear-cell renal cell carcinoma Nivolumab 240 mg/2 weeks plus cabozantinib 40 mg/day (N:323) or sunitinib 50 mg/day,
New Indication: Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Study: Open-label, phase 3 trial Stage IB to IIIA resectable NSCLC Three cycles neoadjuvant treatment Nivolumab plus platinum-based chemotherapy (N:176) or platinum-based chemotherapy (N:176) Efficacy: mEFS: 31.6 m vs 20.8
New Indication: Nivolumab Combination in Advanced Esophageal Squamous-Cell Carcinoma
Study: Global, randomized, open-label, phase 3 trial (CheckMate 648) Unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma with no previous systemic therapy for advanced disease Nivolumab plus chemotherapy (n=321) or